Ethic Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Ethic Inc. reduced its holdings in Regeneron Pharmaceuticals by 33.6% during the first quarter, now owning 7,081 shares worth approximately $4.37 million.
• Regeneron reported $12.89 EPS for its most recent quarter, exceeding the consensus estimate of $8.43, with revenues of $3.68 billion.
• The company declared a quarterly dividend of $0.88 per share, representing a 0.6% yield, with a dividend payout ratio of 8.87%.

Ethic Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 33.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,081 shares of the biopharmaceutical company's stock after selling 3,587 shares during the period. Ethic Inc.'s holdings in Regeneron Pharmaceuticals were worth $4,369,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Element Capital Management LLC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $2,705,000. Aberdeen Group plc grew its holdings in Regeneron Pharmaceuticals by 30.1% during the 1st quarter. Aberdeen Group plc now owns 245,197 shares of the biopharmaceutical company's stock valued at $155,647,000 after buying an additional 56,746 shares during the last quarter. Horizon Investments LLC grew its holdings in Regeneron Pharmaceuticals by 3.7% during the 1st quarter. Horizon Investments LLC now owns 1,634 shares of the biopharmaceutical company's stock valued at $1,036,000 after buying an additional 59 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $1,100,000. Finally, Kovitz Investment Group Partners LLC grew its holdings in Regeneron Pharmaceuticals by 80.5% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 6,929 shares of the biopharmaceutical company's stock valued at $4,395,000 after buying an additional 3,090 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.4%

Regeneron Pharmaceuticals stock traded down $2.13 during midday trading on Tuesday, reaching $571.78. The stock had a trading volume of 854,560 shares, compared to its average volume of 979,587. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The stock has a market capitalization of $60.60 billion, a PE ratio of 14.41, a price-to-earnings-growth ratio of 1.91 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The stock's 50-day simple moving average is $546.30 and its 200 day simple moving average is $593.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the firm earned $11.56 earnings per share. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price on the stock. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, Morgan Stanley restated an "overweight" rating and set a $761.00 price objective (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $829.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.